Skip to content

Opko Health OPK Senior Long Term Notes

Senior Long Term Notes at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$446.9M

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:SeniorLongTermNotes.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's senior long term notes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's senior long term notes?
Opko Health (OPK) reported senior long term notes of $246.64M in Q1 2026.
How has Opko Health's senior long term notes changed year-over-year?
Opko Health's senior long term notes increased by 0.3% year-over-year, from $245.79M to $246.64M.
What does senior long term notes mean?
This represents the principal amount of long-term debt obligations that hold a senior claim on the company's assets in the event of liquidation. These notes typically carry fixed interest rates and are due beyond one year, forming a core component of the company's long-term debt profile. Investors use this to evaluate the company's overall leverage and the cost of servicing its long-term debt obligations.